Clinical Trials
13 trialsNCT05168618 2026-06-05
AtezoCab
University of Utah
Phase 2 Recruiting
NCT04631744 2026-05-01
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Terminated
NCT05265988 2024-07-31
MERIDIAN
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03964337 2022-06-29
SPARC
Duke University
Phase 2 Terminated
NCT01630590 2022-03-25
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01574937 2021-08-06
XL-184+Abiraterone in Post-Chemo CRPC
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01812668 2021-08-05
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT01588821 2020-09-29
Cabozantinib in Advanced Solid Malignancies
Massachusetts General Hospital
Phase 2 Completed
NCT01599793 2020-03-26
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
University of Chicago
Phase 2 Completed
NCT01703065 2018-12-04
Cabozantinib in Men With Castration-Resistant Prostate Cancer
University of Washington
Phase 2 Terminated
NCT01834651 2017-09-27
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Cedars-Sinai Medical Center
Phase 2 Completed
NCT01347788 2016-11-28
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Massachusetts General Hospital
Phase 1 Completed